 Artist: Dobet Gnahore: mp3 download Genre(s): Ethnic Dobet Gnahore's discography:  Ano Neko-Let's Create Together Year: 2004 Tracks: 16 Vocalist, professional dancer, and percussionist Dobet Gnahore has been hailed Africa's leading lead on the go up, compared to writing style legends and ethnic ambassadors wish Miriam Makeba and Hugh Masakela by her twenties. Brought up in a musical and esthetic conservatoire environs, Gnahore's musical natural endowment comes as no surprise. Her forefather, Boni Gnahore, a drummer, vocalist, and performer fame across the Ivory Coast, was a foundation phallus of the artist colony Village Ki-Yi M'Bock, a community of more than 50 artists from multiple disciplines and backgrounds. Her first base esthetic turn peak came when Gnahore was 12 and proclaimed to her father-God that she wasn't going to schoolhouse whatsoever longer, only preferably staying at the colony to see. After years of apprenticeship with some of the continent's most technical artists, Gnahore came upon a mo turning point. French guitarist Colin Laroche de Feline came to the liquidation, his intended three-day visit turning into a three-year residency. Gnahore's and Laroche de Feline's professional and personal lives became woven together, creating a duo called Ano Neko. They fagged significant prison term in both Africa and France (depending on the African political mood) touring and acting. The group's self-titled debut was released in 2004 to enthusiastic critical clap. Two eld later Ano Neko was invited to join the Putumayo Acoustic Africa circuit, which travelled all over Europe and North America. Gnahore and Laroche de Feline second Earl of Guilford Korean won fans and impressed audiences, playacting alongside musical greats Vusi Mahlasela and Habib Koité. Soon to follow was Gnahore's sophomore loss, Na Afriki, which, thanks to her ever so expanding winnow foot, appeared on world music charts like a shot following its button. Laroche de Feline and Gnahore economise a engaged operation schedule patch living with their girl in the French countryside. Gnahore's ease in a wide array of African musical styles has earned her a reputation as presage and rude endowment that will ane day avail chart the course of action for the writing style. |
Wednesday 10 September 2008
Mp3 music: Dobet Gnahore
Sunday 31 August 2008
Why Bill Gates is paying Seinfeld $14m
Comedian Jerry Seinfeld will star in a US$300 million marketing campaign for Microsoft aimed at burnishing the prototype of its computer operating system, a person familiar with the effort said.
The centerpiece of that campaign, to debut next month, is a series of television advertisements in which Seinfeld, 54, best known for his eponymous situation comedy, will seem with Microsoft chairman Bill Gates, the person told Reuters.
The Wall Street Journal, which number one reported inside information of the marketing effort, said Seinfeld will encounter about US$10 million (NZ$13.9m)�for his work.
Seinfeld's representatives were not immediately available for comment and Redmond, Washington-based computer package giant Microsoft declined to discuss the matter.
But the source world Health Organization knew of the ad campaign said an immediate goal of the commercials is to counter populace perceptions that Windows Vista, Microsoft's latest PC operating system, is clunky and hard to use compared with rival products from Apple.
The overall objective of the campaign is to rejuvenate the brand image of Windows generally, the source said.
Devised by the Miami-based ad agency Crispin Porter + Bogusky, the spots will employ some variation of the motto "Windows, Not Walls" and the root word of removing barriers that prevent citizenry and ideas from connecting, the person said.
The ads will begin appearing September 4. The Wall Street Journal aforementioned the $US300 million marketing campaign is one of the largest in the company's history.
For now, Seinfeld is the only celebrity, other than Gates, pickings part in the political campaign, although others were considered, including amusing actor Will Ferrell, the source said.
The attempted ikon overhaul comes in the wake of Apple's "Mac vs PC" ads featuring a geeky PC guy rope who mistily resembles Gates being unable to keep up with a fine-looking, hip Mac counterpart.
Those ads, painting Windows as stodgy and unreliable, have reinforced criticism about Vista's public presentation, stringent hardware requirements and lack of support for other package and devices such as printers.
Despite selling more than 180 one thousand thousand licenses since its launch in 2007, Vista continues to endure from the perception the release was a washout, although Microsoft has aforementioned early problems with the operating system have been resolved.
The Windows operating system is the crown gem of Microsoft's US$60 billion software empire. It sits on more than 90 percent of the world's computers and profits generated from Windows bankroll the company's ventures into new businesses such as Xbox video game machines and Zune music players.
More info
Thursday 21 August 2008
Married Women In India Who Experience Physical, Sexual Abuse By Husbands More Likely To Contract HIV, Study Finds
�
Married women in India whose husbands physically and sexually abuse them ar about four-spot times more likely to contract HIV compared with married women in the country world Health Organization do not experience abuse, according to a cogitation published latterly in the Journal of the American Medical Association, Reuters UK reports. Researchers, led by Jay Silverman of the Harvard School of Public Health, examined data from India's National Family Health Survey betwixt 2005 and 2006. The data included information about 28,139 married women.
More than one-third of the women in the study reported experiencing forcible violence with or without sexual abuse by their husbands. Of these women, 28% experienced only physical violence, while 7.7% reported both physical and sexual clapperclaw. The peril of HIV among the women wHO experienced both physical and sexual force increased by a magnitude of 3.9 compared with women who did not experience abuse, according to the study.
The researchers aforesaid that they confirmed earlier studies indicating that workforce who have extramarital relationships, including unprotected sex with commercial sex workers, are the principal source of HIV among women in India. More than 95% of HIV-positive Indian women report being monogamous, the researchers aforesaid, adding that extramarital relationships on the part of their husbands help explain why many women wHO experience pervert are catching the virus. "A woman who is abused by her hubby is truly placed in a situation of 'double jeopardy' regarding HIV infection," Silverman aforesaid, adding that a husband's "sexual behaviour outside of the spousal relationship makes it more potential he is infected with the virus, and his abusive behaviour inside the marriage leaves her with little over control gender or intimate protection" (Reuters UK, 8/12).
An abstract of the study is available online.
Reprinted with tolerant permission from http://www.kaisernetwork.org. You toilet view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.
Married women in India whose husbands physically and sexually abuse them ar about four-spot times more likely to contract HIV compared with married women in the country world Health Organization do not experience abuse, according to a cogitation published latterly in the Journal of the American Medical Association, Reuters UK reports. Researchers, led by Jay Silverman of the Harvard School of Public Health, examined data from India's National Family Health Survey betwixt 2005 and 2006. The data included information about 28,139 married women.
More than one-third of the women in the study reported experiencing forcible violence with or without sexual abuse by their husbands. Of these women, 28% experienced only physical violence, while 7.7% reported both physical and sexual clapperclaw. The peril of HIV among the women wHO experienced both physical and sexual force increased by a magnitude of 3.9 compared with women who did not experience abuse, according to the study.
The researchers aforesaid that they confirmed earlier studies indicating that workforce who have extramarital relationships, including unprotected sex with commercial sex workers, are the principal source of HIV among women in India. More than 95% of HIV-positive Indian women report being monogamous, the researchers aforesaid, adding that extramarital relationships on the part of their husbands help explain why many women wHO experience pervert are catching the virus. "A woman who is abused by her hubby is truly placed in a situation of 'double jeopardy' regarding HIV infection," Silverman aforesaid, adding that a husband's "sexual behaviour outside of the spousal relationship makes it more potential he is infected with the virus, and his abusive behaviour inside the marriage leaves her with little over control gender or intimate protection" (Reuters UK, 8/12).
An abstract of the study is available online.
Reprinted with tolerant permission from http://www.kaisernetwork.org. You toilet view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.
Monday 11 August 2008
FDA Accepts Streamlined Phase 3 Development Plan For Q8003IR 'Dual Opioid' Pain Therapy
�QRxPharma Limited (ASX: QRX; OTCQX: QRXPY), a clinical-stage specialty
pharmaceutical company focused on the development and commercialization of
therapies for pain and central queasy system (CNS) disorders, proclaimed
today that the U.S. Food and Drug Administration (FDA) accepted its
proposed Phase 3 protocol designs and statistical analyses to demonstrate
the efficacy and safety of Q8003IR, an immediate freeing dual-opioid
(morphine plus oxycodone) product intended for the management of moderate
to severe acute pain. Pending incorporation of the FDA's recommended
modifications, only 2 Phase 3 trials will be needed for NDA filing.
Under this sleek clinical development program, no additional
pharmacology, toxicology or long-term clinical safety studies will be
required for regulatory submission and food market approval.
"This is a significant and positive resultant," said Dr. John Holaday,
Managing Director and Chief Executive Officer, QRxPharma, commenting on the
FDA reappraisal meeting. "Acceptance of QRxPharma's streamlined development plan
for Q8003IR is a measuring stick of success in terms of reduced risk, resource
efficiencies, and potential value of dual opioids. We believe this outcome
serves to reward the soundness of our business strategy - to expand the
clinical utility of existing compounds and deliver new treatments for
targeted indications with chiseled paths to regulatory commendation and
sales."
Following QRxPharma's FDA confluence on July 21, 2008, the Company
reported the Agency had determined no new creature safety studies were
requisite, accepted the design of the proposed combination formula study with
minimal modifications, and establish the proposed number of patients receiving
Q8003IR, as well as the continuance of dosing, sufficient for regulatory
submission of a 505(b)2 NDA.
"No extra clinical studies or measures of safety and efficacy
beyond those proposed by QRxPharma were requested," said Dr. Warren Stern,
Executive Vice President, Drug Development, QRxPharma. "Having successfully
completed an initial Phase 3 trial in April2008, QRxPharma continues to
satisfy FDA requirements and demonstrate the potential of Q8003IR to
provide equal or better analgesia with a diminution of summate opioid dosage and
improved tolerability."
Final Phase 3 studies for Q8003IR will include a combination rule study
in patients experiencing post-surgery (bunionectomy) pain and placebo
controlled study in patients following total genu replacement.
Forward Looking Statements
This press release contains innovative statements. Forward-looking
statements are statements that are not historical facts; they include
statements or so our beliefs and expectations. Any statement in this
release that states our intentions, beliefs, expectations or predictions
(and the assumptions underlying them) is a forward-looking statement. These
statements are based on plans, estimates and projections as they are
currently useable to the management of QRxPharma. Forward-looking
statements therefore speak only as of the date they are made, and we
take in charge no responsibility to update publicly whatever of them in light of new
information or future events.
By their very nature, forward-looking statements involve risks and
uncertainties. A number of authoritative factors could therefore lawsuit actual
results to differ materially from those contained in whatever forward-looking
statement. Such factors include risks relating to the point of products
under development; uncertainties relating to clinical trials; dependency on
third parties; succeeding capital inevitably; and risks relating to the
commercialization of the Company's proposed products.
About QRxPharma
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) is a clinical-stage
specialty pharmaceutic company focussed on the development and
commercialization of new treatments for painfulness management and central aflutter
system (CNS) disorders. Based on a business strategy to expand the clinical
utility and commercial value of marketed and/or existing compounds, the
Company's product portfolio includes both late and early stage clinical
drug candidates with well-defined paths to regulatory approving and sales.
QRxPharma intends to direct commercialize its products in the US and attempt
strategic partnerships abroad. QRxPharma's lead compound, Q8003IR,
completed its low Phase 3 clinical trial in April 2008, having met all
primary and secondary endpoints. The Company's preclinical and clinical
pipeline includes other technologies in the fields of pain management,
neurodegenerative disease and venomics. For more information:
http://www.QRxPharma.com.
QRxPharma Limited
http://www.QRxPharma.com
More info
pharmaceutical company focused on the development and commercialization of
therapies for pain and central queasy system (CNS) disorders, proclaimed
today that the U.S. Food and Drug Administration (FDA) accepted its
proposed Phase 3 protocol designs and statistical analyses to demonstrate
the efficacy and safety of Q8003IR, an immediate freeing dual-opioid
(morphine plus oxycodone) product intended for the management of moderate
to severe acute pain. Pending incorporation of the FDA's recommended
modifications, only 2 Phase 3 trials will be needed for NDA filing.
Under this sleek clinical development program, no additional
pharmacology, toxicology or long-term clinical safety studies will be
required for regulatory submission and food market approval.
"This is a significant and positive resultant," said Dr. John Holaday,
Managing Director and Chief Executive Officer, QRxPharma, commenting on the
FDA reappraisal meeting. "Acceptance of QRxPharma's streamlined development plan
for Q8003IR is a measuring stick of success in terms of reduced risk, resource
efficiencies, and potential value of dual opioids. We believe this outcome
serves to reward the soundness of our business strategy - to expand the
clinical utility of existing compounds and deliver new treatments for
targeted indications with chiseled paths to regulatory commendation and
sales."
Following QRxPharma's FDA confluence on July 21, 2008, the Company
reported the Agency had determined no new creature safety studies were
requisite, accepted the design of the proposed combination formula study with
minimal modifications, and establish the proposed number of patients receiving
Q8003IR, as well as the continuance of dosing, sufficient for regulatory
submission of a 505(b)2 NDA.
"No extra clinical studies or measures of safety and efficacy
beyond those proposed by QRxPharma were requested," said Dr. Warren Stern,
Executive Vice President, Drug Development, QRxPharma. "Having successfully
completed an initial Phase 3 trial in April2008, QRxPharma continues to
satisfy FDA requirements and demonstrate the potential of Q8003IR to
provide equal or better analgesia with a diminution of summate opioid dosage and
improved tolerability."
Final Phase 3 studies for Q8003IR will include a combination rule study
in patients experiencing post-surgery (bunionectomy) pain and placebo
controlled study in patients following total genu replacement.
Forward Looking Statements
This press release contains innovative statements. Forward-looking
statements are statements that are not historical facts; they include
statements or so our beliefs and expectations. Any statement in this
release that states our intentions, beliefs, expectations or predictions
(and the assumptions underlying them) is a forward-looking statement. These
statements are based on plans, estimates and projections as they are
currently useable to the management of QRxPharma. Forward-looking
statements therefore speak only as of the date they are made, and we
take in charge no responsibility to update publicly whatever of them in light of new
information or future events.
By their very nature, forward-looking statements involve risks and
uncertainties. A number of authoritative factors could therefore lawsuit actual
results to differ materially from those contained in whatever forward-looking
statement. Such factors include risks relating to the point of products
under development; uncertainties relating to clinical trials; dependency on
third parties; succeeding capital inevitably; and risks relating to the
commercialization of the Company's proposed products.
About QRxPharma
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) is a clinical-stage
specialty pharmaceutic company focussed on the development and
commercialization of new treatments for painfulness management and central aflutter
system (CNS) disorders. Based on a business strategy to expand the clinical
utility and commercial value of marketed and/or existing compounds, the
Company's product portfolio includes both late and early stage clinical
drug candidates with well-defined paths to regulatory approving and sales.
QRxPharma intends to direct commercialize its products in the US and attempt
strategic partnerships abroad. QRxPharma's lead compound, Q8003IR,
completed its low Phase 3 clinical trial in April 2008, having met all
primary and secondary endpoints. The Company's preclinical and clinical
pipeline includes other technologies in the fields of pain management,
neurodegenerative disease and venomics. For more information:
http://www.QRxPharma.com.
QRxPharma Limited
http://www.QRxPharma.com
More info
Wednesday 6 August 2008
Kanye West, Ludacris join 'Three Ringz'
Third T-Pain album referable in the fall on Jive
NEW YORK -- Ludacris, Kanye West and Chris Brown own joined the roster of guest artists on T-Pain's third album, "Three Ringz," due in the fall down via Jive. Official commencement single "Can't Believe It" featuring Lil Wayne is No. 50 in its third workweek on Billboard's Hot R&B/Hip-Hop Songs chart.
Elsewhere, Chris Brown appears on the saltation track "Freeze," while Ludacris guests on "Chopped & Screwed," DJ Khaled lends a hand on "Karaoke" and West joins the fun on "Therapy."
"Three Ringz" follows 2007's "Epiphany," which has sold 830,000 copies in the United States, according to Nielsen SoundScan.
T-Pain remains a mending on the charts with guest appearances. He bathroom currently be heard guesting on Lil Wayne's "Got Money," DJ Khaled's "Out Here Grindin,' " Rick Ross' "The Boss," Mike Jones' "Cuddy Buddy" and Tay Dizm's "Beam Me Up."
As previously reported, the latter is the first signee to T-Pain's digital-only Nappy Boy label.
NEW YORK -- Ludacris, Kanye West and Chris Brown own joined the roster of guest artists on T-Pain's third album, "Three Ringz," due in the fall down via Jive. Official commencement single "Can't Believe It" featuring Lil Wayne is No. 50 in its third workweek on Billboard's Hot R&B/Hip-Hop Songs chart.
Elsewhere, Chris Brown appears on the saltation track "Freeze," while Ludacris guests on "Chopped & Screwed," DJ Khaled lends a hand on "Karaoke" and West joins the fun on "Therapy."
"Three Ringz" follows 2007's "Epiphany," which has sold 830,000 copies in the United States, according to Nielsen SoundScan.
T-Pain remains a mending on the charts with guest appearances. He bathroom currently be heard guesting on Lil Wayne's "Got Money," DJ Khaled's "Out Here Grindin,' " Rick Ross' "The Boss," Mike Jones' "Cuddy Buddy" and Tay Dizm's "Beam Me Up."
As previously reported, the latter is the first signee to T-Pain's digital-only Nappy Boy label.
Wednesday 25 June 2008
Sunday 22 June 2008
Celeb photographer accused of stalking Jamie Lynn Spears, fiance
JACKSON, Miss. - A celebrity photographer accused of stalking Jamie Lynn Spears and her fiance in a small Mississippi town has been arrested.
Edwin W. Merino, 30, of Los Angeles, posted bond Tuesday. He is scheduled to appear in court next week. Authorities in Liberty, a small town in southwest Mississippi near the Louisiana border, said Merino wouldn't leave the pregnant Spears and her fiance, Casey Aldridge, alone.
Merino denied the accusations in a phone interview Wednesday with The Associated Press. He said that he was about 60 metres away from the couple using a long lens when he was arrested at a gas station.
The younger Spears and Aldridge have been the subject of intense attention since she announced her pregnancy in December. She said then she was 12 weeks along, which would make the 17-year-old due any time.
Merino said he had little luck taking pictures of the couple and was preparing to leave the area.
"I've seen the young man Casey in pictures," Merino said. "I haven't worked on them myself. The first time I got a good look at him was in court."
Spears' family representatives did not immediately return messages Wednesday.
Merino has worked as a celebrity photographer for five years. He was one of the paparazzi who snared pictures of Jamie Lynn Spears' older sister, Britney, without underwear.
Merino said he was the only photographer following Spears during most of his four days in the Liberty area.
"I just think since I was the only one there, it was just easier for them to single me out," Merino said.
Merino's arrest was first reported by the McComb Enterprise-Journal.
Merino said he didn't spend any significant time in jail. A deputy drove him to three automated teller machines and he got the $1,143 he needed to be released.
In the end, Merino said the trip was a waste.
"The one picture I got was kind of by luck," he said. "I got lucky when I saw them at Wal-Mart when I was buying deodorant."
See Also
Subscribe to:
Posts (Atom)